C3G
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127) | Apellis Pharmaceuticals, Inc. | 2021-11-12 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NCT04572854) | Apellis Pharmaceuticals, Inc. | 2021-09-07 |
| Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (NCT04817618) | Novartis Pharmaceuticals | 2021-07-28 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 (NCT02682407) | Omeros Corporation | 2016-03-10 |
| C3G/Primary IC-MPGN EAP (NCT04729062) | Apellis Pharmaceuticals, Inc. |
Track C3G automatically
Every clearance here is in the API, with alerts when new ones post.